Phathom Pharmaceuticals to Participate in Upcoming Investor Conferences
PorAinvest
lunes, 25 de agosto de 2025, 8:04 am ET1 min de lectura
PHAT--
Management representatives from Phathom Pharmaceuticals will conduct one-on-one meetings throughout both conferences. These events are expected to provide investors with a comprehensive overview of the company's pipeline, current market position, and future growth prospects.
The Cantor Global Healthcare Conference 2025 will take place in New York, NY, from September 3 to 5, 2025. The live webcast for the Phathom Pharmaceuticals presentation is scheduled for September 3 at 9:10 am EDT. The H.C. Wainwright 27th Annual Global Investment Conference will be held in New York, NY, from September 8 to 10, 2025, with the live webcast for Phathom Pharmaceuticals' presentation set for September 8 at 1:00 pm EDT. Both webcasts and archived recordings will be available on the Phathom Pharmaceuticals website for up to 90 days following the events [1].
Phathom Pharmaceuticals markets vonoprazan, a first-in-class potassium-competitive acid blocker (PCAB), for various gastrointestinal conditions including Non-Erosive GERD and H. pylori infection treatment in the United States [2].
References:
[1] https://www.marketscreener.com/news/phathom-pharmaceuticals-to-participate-in-upcoming-investor-conferences-ce7c50d8d889f324
[2] https://www.stocktitan.net/news/PHAT/phathom-pharmaceuticals-to-participate-in-upcoming-investor-nnibl7okihup.html
Phathom Pharmaceuticals will participate in the Cantor Global Healthcare Conference 2025 and H.C. Wainwright 27th Annual Global Investment Conference in September. Management will participate in 1x1 meetings throughout the conferences and there will be live webcasts. The company markets vonoprazan for various gastrointestinal diseases in the US.
Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal (GI) diseases, has announced its participation in two upcoming investor conferences in September 2025. The company will present at the Cantor Global Healthcare Conference on September 3 at 9:10 am EDT and the H.C. Wainwright 27th Annual Global Investment Conference on September 8 at 1:00 pm EDT.Management representatives from Phathom Pharmaceuticals will conduct one-on-one meetings throughout both conferences. These events are expected to provide investors with a comprehensive overview of the company's pipeline, current market position, and future growth prospects.
The Cantor Global Healthcare Conference 2025 will take place in New York, NY, from September 3 to 5, 2025. The live webcast for the Phathom Pharmaceuticals presentation is scheduled for September 3 at 9:10 am EDT. The H.C. Wainwright 27th Annual Global Investment Conference will be held in New York, NY, from September 8 to 10, 2025, with the live webcast for Phathom Pharmaceuticals' presentation set for September 8 at 1:00 pm EDT. Both webcasts and archived recordings will be available on the Phathom Pharmaceuticals website for up to 90 days following the events [1].
Phathom Pharmaceuticals markets vonoprazan, a first-in-class potassium-competitive acid blocker (PCAB), for various gastrointestinal conditions including Non-Erosive GERD and H. pylori infection treatment in the United States [2].
References:
[1] https://www.marketscreener.com/news/phathom-pharmaceuticals-to-participate-in-upcoming-investor-conferences-ce7c50d8d889f324
[2] https://www.stocktitan.net/news/PHAT/phathom-pharmaceuticals-to-participate-in-upcoming-investor-nnibl7okihup.html

Divulgación editorial y transparencia de la IA: Ainvest News utiliza tecnología avanzada de Modelos de Lenguaje Largo (LLM) para sintetizar y analizar datos de mercado en tiempo real. Para garantizar los más altos estándares de integridad, cada artículo se somete a un riguroso proceso de verificación con participación humana.
Mientras la IA asiste en el procesamiento de datos y la redacción inicial, un miembro editorial profesional de Ainvest revisa, verifica y aprueba de forma independiente todo el contenido para garantizar su precisión y cumplimiento con los estándares editoriales de Ainvest Fintech Inc. Esta supervisión humana está diseñada para mitigar las alucinaciones de la IA y garantizar el contexto financiero.
Advertencia sobre inversiones: Este contenido se proporciona únicamente con fines informativos y no constituye asesoramiento profesional de inversión, legal o financiero. Los mercados conllevan riesgos inherentes. Se recomienda a los usuarios que realicen una investigación independiente o consulten a un asesor financiero certificado antes de tomar cualquier decisión. Ainvest Fintech Inc. se exime de toda responsabilidad por las acciones tomadas con base en esta información. ¿Encontró un error? Reportar un problema

Comentarios
Aún no hay comentarios